KR20040027972A - 악성 종양의 전이 억제 또는 재발 방지를 위한 다당류콘쥬게이트를 함유하는 약제학적 조성물 - Google Patents

악성 종양의 전이 억제 또는 재발 방지를 위한 다당류콘쥬게이트를 함유하는 약제학적 조성물 Download PDF

Info

Publication number
KR20040027972A
KR20040027972A KR10-2004-7002566A KR20047002566A KR20040027972A KR 20040027972 A KR20040027972 A KR 20040027972A KR 20047002566 A KR20047002566 A KR 20047002566A KR 20040027972 A KR20040027972 A KR 20040027972A
Authority
KR
South Korea
Prior art keywords
glycyl
glycine
polysaccharide
group
pharmaceutical composition
Prior art date
Application number
KR10-2004-7002566A
Other languages
English (en)
Korean (ko)
Inventor
가와구찌다까유끼
오꾸노사또시
야노도시로
Original Assignee
다나베 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다나베 세이야꾸 가부시키가이샤 filed Critical 다나베 세이야꾸 가부시키가이샤
Publication of KR20040027972A publication Critical patent/KR20040027972A/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
KR10-2004-7002566A 2001-08-21 2002-08-16 악성 종양의 전이 억제 또는 재발 방지를 위한 다당류콘쥬게이트를 함유하는 약제학적 조성물 KR20040027972A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2001-00249717 2001-08-21
JP2001249717 2001-08-21
PCT/JP2002/008309 WO2003015826A1 (en) 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor

Publications (1)

Publication Number Publication Date
KR20040027972A true KR20040027972A (ko) 2004-04-01

Family

ID=19078678

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7002566A KR20040027972A (ko) 2001-08-21 2002-08-16 악성 종양의 전이 억제 또는 재발 방지를 위한 다당류콘쥬게이트를 함유하는 약제학적 조성물

Country Status (18)

Country Link
EP (1) EP1418947A1 (uk)
KR (1) KR20040027972A (uk)
CN (1) CN100372570C (uk)
AR (1) AR035137A1 (uk)
AU (1) AU2002328093B2 (uk)
BR (1) BR0212036A (uk)
CA (1) CA2457056C (uk)
HU (1) HUP0401351A3 (uk)
IL (1) IL160148A0 (uk)
MX (1) MXPA04001599A (uk)
NO (1) NO20041194L (uk)
NZ (1) NZ530947A (uk)
PL (1) PL368319A1 (uk)
RU (1) RU2275913C2 (uk)
TW (1) TWI313609B (uk)
UA (1) UA75450C2 (uk)
WO (1) WO2003015826A1 (uk)
ZA (1) ZA200400917B (uk)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
FR2914305B1 (fr) 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
EP3693454A1 (en) 2008-07-16 2020-08-12 Children's Medical Center Corporation Organ mimic device with microchannels and methods of use and manufacturing thereof
AU2012262139B2 (en) * 2011-06-02 2017-02-23 Children's Medical Center Corporation Methods and uses for ex vivo tissue culture systems
PL221351B1 (pl) 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych
KR102087017B1 (ko) 2012-10-11 2020-03-10 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
EP2910573B1 (en) * 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
TWI718144B (zh) 2015-05-04 2021-02-11 美商輝瑞股份有限公司 B型鏈球菌多醣-蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
BR112017027690A2 (pt) 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
EP3552626A4 (en) 2016-12-12 2020-06-10 Daiichi Sankyo Company, Limited ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR
JP6679762B2 (ja) 2017-01-17 2020-04-15 第一三共株式会社 抗gpr20抗体及び抗gpr20抗体−薬物コンジュゲート
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
CN117838880A (zh) 2017-08-31 2024-04-09 第一三共株式会社 制备抗体-药物缀合物的新方法
EP3677589A4 (en) 2017-08-31 2021-04-21 Daiichi Sankyo Company, Limited IMPROVED PROCESS FOR PREPARING ANTIBODY-ACTIVE CONJUGATE
CN117815404A (zh) 2018-05-18 2024-04-05 第一三共株式会社 抗-muc1抗体-药物缀合物
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0640622T3 (da) * 1993-02-26 2000-10-23 Drug Delivery System Inst Ltd Polysaccharidderivat og lægemiddelbærer
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
WO1997038727A1 (fr) * 1996-04-15 1997-10-23 Asahi Kasei Kogyo Kabushiki Kaisha Composite medicamenteux
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CN1058038C (zh) * 1996-12-31 2000-11-01 中国科学院感光化学研究所 低收缩性光固化涂层材料及其制法和用途
EA003398B1 (ru) * 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем

Also Published As

Publication number Publication date
CA2457056A1 (en) 2003-02-27
ZA200400917B (en) 2004-08-25
RU2004108141A (ru) 2005-04-20
AU2002328093B2 (en) 2005-05-05
IL160148A0 (en) 2004-07-25
CN1545423A (zh) 2004-11-10
PL368319A1 (en) 2005-03-21
NO20041194L (no) 2004-03-19
CA2457056C (en) 2008-07-22
TWI313609B (en) 2009-08-21
NZ530947A (en) 2006-04-28
BR0212036A (pt) 2004-08-17
CN100372570C (zh) 2008-03-05
MXPA04001599A (es) 2004-07-08
UA75450C2 (en) 2006-04-17
EP1418947A1 (en) 2004-05-19
AR035137A1 (es) 2004-04-14
WO2003015826A1 (en) 2003-02-27
RU2275913C2 (ru) 2006-05-10
HUP0401351A3 (en) 2011-02-28
HUP0401351A2 (hu) 2004-12-28

Similar Documents

Publication Publication Date Title
EP0640622B1 (en) Polysaccharide derivative and drug carrier
RU2275913C2 (ru) Фармацевтические композиции, включающие полисахаридные конъюгаты, для ингибирования метастазов или предотвращения рецидива злокачественной опухоли
US6436912B1 (en) Drug complexes
US5892043A (en) Camptothecin derivatives
JP4717016B2 (ja) O,o’−アミドマロネートおよびn,o−アミドマロネート白金錯体
AU2002328093A1 (en) Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor
EA003398B1 (ru) Лекарственный комплекс c полимерным носителем
EA026870B1 (ru) Комбинация и фармацевтическая композиция для лечения опухолей
JPH1192405A (ja) 薬物複合体
US20060052288A1 (en) Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
JPH1171280A (ja) 医薬組成物
ES2394590T3 (es) Endostatina humana recombinante modificada y su aplicación
JP2527885B2 (ja) ヘパリン誘導体
JP2003137818A (ja) 悪性腫瘍の転移抑制または再発予防用組成物
EP3071238B1 (en) Conjugate comprising indole-3-carbinol for medical use
JP2019156771A (ja) ペメトレキセド−ヒアルロン酸結合体
CA2754846A1 (en) Prostate-specific antigen cleavable prodrugs
KR100481434B1 (ko) 약물복합체의제조방법
MX2014010209A (es) Agente inhibidor para acumulacion de fluido de la cavidad corporal.
JPH04103538A (ja) 制癌剤副作用抑制剤

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E601 Decision to refuse application
J201 Request for trial against refusal decision
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20060714

Effective date: 20070828